Is Artivion, Inc. (AORT) a good stock to buy?

Olyth's institutional analysis of AORT reveals an Altman Z-Score of 3.13 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($0.44B most recent), help investors decide if AORT fits their risk profile.

What is the current P/E ratio for AORT?

As of the latest trading session, Artivion, Inc. (AORT) has a trailing P/E ratio of 169.90.

Who is the CEO of Artivion, Inc.?

The current Chief Executive Officer of Artivion, Inc. is James Patrick Mackin.

What was AORT's revenue for the last 5 years?

According to its latest income statements, Artivion, Inc. reported annual revenues of $0.44B (2025), $0.39B (2024), $0.35B (2023), $0.31B (2022), $0.30B (2021) respectively.

Does AORT pay a dividend?

Artivion, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does AORT have?

In its latest reporting period, Artivion, Inc. generated $-0.00B in Free Cash Flow against a total debt load of $0.29B.

What is the Price-to-Book (P/B) ratio of Artivion, Inc.?

The Price-to-Book (P/B) ratio for Artivion, Inc. (AORT) is currently 3.70.

What is the Price-to-Sales (P/S) ratio of AORT?

Based on trailing twelve-month data, Artivion, Inc. (AORT) trades at a Price-to-Sales (P/S) ratio of 3.79.

What is Artivion, Inc.'s Return on Equity (ROE)?

Artivion, Inc. (AORT) has a Return on Equity (ROE) of 2.44%, representing its profitability relative to shareholder equity.

AORT

Artivion, Inc. · Healthcare

34.90

4.32%(+1.45)

Market Open

Last Updated: — ET

52W L: $21.9752W H: $48.25

$34.87

CHG-1.53 (-4.20%)

H$38.80

L$32.84

VOL7.1M

AORT (1h)

Company Profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Sector

Healthcare

Industry

Medical - Devices

Employees

1,600

IPO Date

1993-02-12

Beta

1.62

Websiteartivion.com↗

AORT

Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT

Artivion (NYSE:AORT) Shares Gap Down – Should You Sell?

Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Analysts

Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript